National Pension Service Sells 146,486 Shares of Labcorp Holdings Inc. $LH

Key Points

• National Pension Service cut its Labcorp stake by 77.2%, selling 146,486 shares and retaining 43,150 shares valued at approximately $12.1 million. Institutional investors still own about 95.94% of the company.
• Labcorp reported quarterly EPS of $4.99, beating the $4.78 analyst consensus, while revenue rose 5.8% year over year to $3.73 billion. The company reaffirmed its 2026 adjusted EPS guidance of $18.10–$18.55 and issued long-term targets for 5%–8% annual revenue growth through 2029.
• Shares recently traded around $311, below the consensus analyst target of $336.36, with a “Moderate Buy” rating. Labcorp also pays a quarterly dividend of $0.72, equivalent to an annualized yield of about 0.9%.

National Pension Service trimmed its stake in Labcorp Holdings Inc. (NYSE:LH - Free Report) by 77.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 43,150 shares of the medical research company's stock after selling 146,486 shares during the period. National Pension Service owned about 0.05% of Labcorp worth $12,082,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in LH. Hilton Head Capital Partners LLC bought a new stake in Labcorp in the 4th quarter valued at $27,000. JPL Wealth Management LLC bought a new stake in Labcorp in the third quarter valued at about $28,000. DV Equities LLC acquired a new position in Labcorp in the fourth quarter worth about $29,000. Allied Private Wealth LLC bought a new position in Labcorp during the second quarter worth about $33,000. Finally, EFG International AG acquired a new stake in Labcorp during the fourth quarter valued at approximately $33,000. 95.94% of the stock is currently owned by institutional investors.

Labcorp News Roundup

Here are the key news stories impacting Labcorp this week:

• Positive Sentiment: Labcorp reaffirmed its 2026 guidance of adjusted EPS of $18.10 to $18.55, broadly consistent with the analyst consensus of $18.32. Maintaining guidance supports confidence in near-term earnings visibility. Labcorp Holdings Reiterates 2026 Outlook, Issues Long-Term Guidance
• Positive Sentiment: The company issued a 2029 outlook calling for compound annual revenue growth of 5% to 8% and adjusted EPS growth of 8.5% to 11.5%. The targets imply sustained expansion beyond the current year and could support a higher long-term earnings outlook. Labcorp 2026 Investor Day Announcement
• Positive Sentiment: Labcorp plans to use artificial intelligence, specialty testing, scientific capabilities and global scale to drive growth. Management also emphasized strong cash-flow generation and disciplined capital deployment, which may improve shareholder returns if execution meets expectations. Labcorp Bets Big on AI and Specialty Testing
• Neutral Sentiment: The Investor Day transcript provided additional detail on Labcorp’s strategic priorities and long-term financial framework, but the benefits depend on successful implementation and investment in new technologies and testing capabilities. Labcorp Analyst and Investor Day Transcript
• Negative Sentiment: LH recently declined about 4.3% and underperformed peers, indicating that investors may have viewed the Investor Day information as insufficient to justify the stock’s elevated valuation or may have taken profits despite the favorable long-term targets. Labcorp Stock Heads Into the Open After a 4.3 Percent Slide

Insiders Place Their Bets

In other Labcorp news, EVP Amy B. Summy sold 924 shares of the firm's stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $306.74, for a total value of $283,427.76. Following the completion of the sale, the executive vice president owned 6,956 shares in the company, valued at approximately $2,133,683.44. This trade represents a 11.73% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Kathryn W. Kyle sold 92 shares of the company's stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $286.19, for a total transaction of $26,329.48. Following the transaction, the executive vice president owned 3,904 shares in the company, valued at $1,117,285.76. The trade was a 2.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 8,919 shares of company stock valued at $2,826,593 over the last three months. Company insiders own 0.84% of the company's stock.

Labcorp Stock Performance

NYSE:LH opened at $311.36 on Friday. The stock has a market capitalization of $25.25 billion, a P/E ratio of 25.75, a price-to-earnings-growth ratio of 1.77 and a beta of 0.88. The company has a current ratio of 1.80, a quick ratio of 1.53 and a debt-to-equity ratio of 0.69. Labcorp Holdings Inc. has a 1 year low of $244.52 and a 1 year high of $341.80. The firm has a 50 day moving average of $310.39 and a 200-day moving average of $281.94.

Labcorp (NYSE:LH - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The medical research company reported $4.99 EPS for the quarter, topping analysts' consensus estimates of $4.78 by $0.21. Labcorp had a return on equity of 16.74% and a net margin of 6.99%.The business had revenue of $3.73 billion for the quarter, compared to analyst estimates of $3.71 billion. During the same period in the prior year, the company earned $4.35 EPS. Labcorp's revenue for the quarter was up 5.8% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. As a group, sell-side analysts anticipate that Labcorp Holdings Inc. will post 18.32 EPS for the current fiscal year.

Labcorp Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 28th were paid a $0.72 dividend. The ex-dividend date was Friday, August 28th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.9%. Labcorp's dividend payout ratio (DPR) is 23.82%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on LH shares. UBS Group increased their target price on Labcorp from $361.00 to $380.00 and gave the stock a "buy" rating in a report on Friday. Wall Street Zen upgraded Labcorp from a "hold" rating to a "buy" rating in a research report on Sunday, July 12th. Bank of America increased their price objective on Labcorp from $300.00 to $320.00 and gave the stock a "buy" rating in a research note on Monday, July 13th. Mizuho set a $355.00 price objective on Labcorp in a report on Monday, August 10th. Finally, Barclays boosted their target price on shares of Labcorp from $320.00 to $330.00 and gave the company an "equal weight" rating in a research note on Friday. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $336.36.

About Labcorp

Labcorp NYSE: LH, formerly Laboratory Corporation of America Holdings, is a global life sciences and laboratory services company headquartered in Burlington, North Carolina. The company provides diagnostic testing and related services to physicians, hospitals, health systems, employers, government agencies and consumers.

Its diagnostics business offers routine and specialty laboratory testing, including molecular, genetic, oncology, women's health, infectious disease and pathology services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.